Skip to main content Back to Top
Advertisement

9/3/2019

Fentanyl Citrate Injection

Products Affected - Description

    • Fentanyl citrate solution for injection, Hikma, 50 mcg/mL, 20 mL vial, 25 count, NDC 00641-6029-25
    • Fentanyl citrate solution for injection, Pfizer, 50 mcg/mL, 2 mL Carpuject syringe, 10 count, NDC 00409-1276-32
    • Fentanyl citrate solution for injection, Pfizer, 50 mcg/mL, 2 mL vial, 25 count, NDC 00409-9094-22
    • Fentanyl citrate solution for injection, Pfizer, 50 mcg/mL, 20 mL vial, 25 count, NDC 00409-9094-31
    • Fentanyl citrate solution for injection, Pfizer, 50 mcg/mL, 50 mL vial, 25 count, NDC 00409-9094-61

Reason for the Shortage

    • Akorn has fentanyl injection available. They are not currently marketing 25 count fentanyl ampules.
    • Hikma has fentanyl injection on shortage due to supply and demand issues. They are not currently marketing fentanyl ampules, just vials.
    • Pfizer has fentanyl injection on shortage due to manufacturing delays. The 20 mL ampules were discontinued in September 2017.
    • Fresenius Kabi has fentanyl injection available.

Available Products

    • Fentanyl citrate solution for injection, Akorn, 50 mcg/mL, 2 mL ampule, 10 count, NDC 17478-0030-02
    • Fentanyl citrate solution for injection, Akorn, 50 mcg/mL, 5 mL ampule, 10 count, NDC 17478-0030-05
    • Fentanyl citrate solution for injection, Fresenius Kabi, 50 mcg/mL, 1 mL vial, 25 count, NDC 63323-0806-01
    • Fentanyl citrate solution for injection, Fresenius Kabi, 50 mcg/mL, 2 mL vial, 25 count, NDC 63323-0806-02
    • Fentanyl citrate solution for injection, Fresenius Kabi, 50 mcg/mL, 20 mL vial, 25 count, NDC 63323-0806-20
    • Fentanyl citrate solution for injection, Fresenius Kabi, 50 mcg/mL, 5 mL vial, 25 count, NDC 63323-0806-05
    • Fentanyl citrate solution for injection, Fresenius Kabi, 50 mcg/mL, 50 mL vial, 1 count, NDC 63323-0806-50
    • Fentanyl citrate solution for injection, Hikma, 50 mcg/mL, 2 mL vial, 25 count, NDC 00641-6027-25
    • Fentanyl citrate solution for injection, Hikma, 50 mcg/mL, 5 mL vial, 25 count, NDC 00641-6028-25
    • Fentanyl citrate solution for injection, Hikma, 50 mcg/mL, 50 mL vial, 1 count, NDC 00641-6030-01
    • Fentanyl citrate solution for injection, Pfizer, 50 mcg/mL, 10 mL vial, 25 count, NDC 00409-9094-28
    • Fentanyl citrate solution for injection, Pfizer, 50 mcg/mL, 2 mL ampule, 10 count, NDC 00409-9093-32
    • Fentanyl citrate solution for injection, Pfizer, 50 mcg/mL, 5 mL ampule, 10 count, NDC 00409-9093-35
    • Fentanyl citrate solution for injection, Pfizer, 50 mcg/mL, 5 mL vial, 25 count, NDC 00409-9094-25

Estimated Resupply Dates

    • Hikma has fentanyl 50 mcg/mL 20 mL vials on back order and the company estimates a release date of mid-September 2019.
    • Pfizer has fentanyl 50 mcg/mL 2 mL, 20 mL, and 50 mL vials on back order and the company estimates a release date of September 2019 for the 2 mL and 50 mL vials and November 2019 for the 20 mL vials. The 2 mL Carpuject syringes are on back order and the company estimates a release date of August 2020.

Implications for Patient Care

    • ASHP has an FAQ on the injectable opioid shortage at https://www.ashp.org/Drug-Shortages/Shortage-Resources/Injectable-Opioid-Shortages-FAQ. This discusses multiple issues including inventory and pharmacy operational strategies.

Updated

Updated September 3, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 8, 2017 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins